Thrombolysis Versus Reoperation in the Management of Prosthetic Valve Thrombosis

Caceres-Loriga, Fidel Manuel; Santos-Gracias, José; Pérez-López, Horacio

doi:10.1016/j.amjcard.2011.06.001

Cited by 8 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In published surgical reports, valve thrombosis is considered any thrombosis unrelated to infection, attached to or within close proximity of the valve per se, thus occluding the path of blood flow, interfering with valve function, or sufficiently large so as to warrant treatment (15) patients to overt syncope, acute heart failure, and, in its most severe form, cardiogenic shock due to mechanical obstruction (34,35). Progressive dyspnea is perhaps the most common clinical presentation (20,21).…”

Section: Definition and Diagnosis Of Bpvtmentioning

confidence: 99%

Bioprosthetic Valve Thrombosis

Puri

Auffret

Rodés‐Cabau

2017

Journal of the American College of Cardiology

147

120

View full text Add to dashboard Cite

Bioprosthetic valve (BPV) thrombosis is considered a relatively rare clinical entity. Yet a more recent analysis involving a more systematic echocardiographic follow-up, the advent of transcatheter heart valve (THV) technologies coupled with the highly sensitive nature of 4-dimensional computed tomographic imaging for detecting subclinical thrombi upon both surgically implanted and THVs, has generated enormous interest in this field, casting new light on both its true incidence and clinical relevance. Debate continues among clinicians as to both the clinical relevance of subclinical BPV thrombosis and the value of empirical oral anticoagulation following BPV implantation. Furthermore, currently no systematic, prospective data exist regarding the optimal treatment approach in THV recipients. The authors provide an overview of the clinical and subclinical spectrum of BPV thrombosis of surgical and THVs, outline its diagnostic challenges, summarize its pathophysiological basis, and discuss various therapeutic options that are emerging, particularly within the rapidly expanding field of THV implantation.

show abstract

Section: Definition and Diagnosis Of Bpvtmentioning

confidence: 99%

Bioprosthetic Valve Thrombosis

Puri

Auffret

Rodés‐Cabau

2017

Journal of the American College of Cardiology

147

120

View full text Add to dashboard Cite

show abstract

“…For this purpose, we show the results of our small-sample study of schizophrenic patients on long-term clozapine, a drug that consistently raises CRP levels, where we evidenced that women had lower CRP increases than men (about a half) in response to a constant stimulus as clozapine long-term treatment. Also, we found that elevated CRP levels were associated with high levels of cholesterol, low-density lipoprotein and body mass index (2).…”

Section: Sayın Editörmentioning

confidence: 58%

“…The American Heart Association and American College of Cardiology reserve thrombolysis only for patients with nonobstructive PVT and hemodynamic stability. The American College of Chest Physicians recommends that the main criterion in the therapeutic decision be the size of thrombus, indicating thrombolysis as the treatment choice if the thrombus has an area of +0.8 cm 2 and surgery in older thrombi. On the basis of the evidence displayed in many studies and our experience over more 20 years, our working group suggests that continuing the search for the best therapy for PVT is no longer necessary.…”

Section: Sayın Editörmentioning

confidence: 99%

See 1 more Smart Citation

Ischemic stroke in the course of thrombolytic treatment of prosthetic valve thrombosis: thrombolysis is suggested

Caceres-Loriga¹

2013

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

“…But these interventions were generally performed in pure renal artery thrombus. Thrombolytic therapy is effective in the treatment of PVT [13][14][15][16]. In patients with nonobstructive thrombosis, thrombolytic therapy is the first-line therapy [13][14][15][16].…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of renal artery thromboembolism with low-dose prolonged infusion of tissue-typed plasminogen activator in a patient with mitral mechanical heart valve thrombosis under the guidance of multimodality imaging

Aykan¹,

Gürsoy²,

Özkan³

et al. 2012

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

This case report describes the use of low-dose prolonged infusion of tissue-typed plasminogen activator in the treatment of renal artery thromboembolism secondary to prosthetic valve thrombosis, under the guidance of multimodality imaging. Thromboembolic occlusion of renal arteries is a rare disorder with serious consequences. It is generally associated with cardiac diseases and arrhytmias. Four consecutive doses of low-dose prolonged infusion of tissue-typed plasminogen activator [25 mg tissue-typed plasminogen activator (tpa) in 6 h] were administered to the patient. This case of renal artery thromboembolism secondary to mitral mechanical prosthetic valve thrombosis was successfully treated with low-dose prolonged infusion of tPA under the guidance of multimodality imaging with renal artery Doppler ultrasonography, multislice computerized tomographic angiography, renal angiography, two-dimensional and real-time three-dimensional transesophageal echocardiography. This case has demonstrated that low-dose prolonged infusion of tissue-typed plasminogen activator may be effective and well tolerated in the treatment of renal embolism.

show abstract

Thrombolysis Versus Reoperation in the Management of Prosthetic Valve Thrombosis

Cited by 8 publications

References 8 publications

Bioprosthetic Valve Thrombosis

Bioprosthetic Valve Thrombosis

Ischemic stroke in the course of thrombolytic treatment of prosthetic valve thrombosis: thrombolysis is suggested

Successful treatment of renal artery thromboembolism with low-dose prolonged infusion of tissue-typed plasminogen activator in a patient with mitral mechanical heart valve thrombosis under the guidance of multimodality imaging

Contact Info

Product

Resources

About